Trial Profile
A Phase III Study Testing the Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic Renal Cell Carcinoma Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Axitinib (Primary) ; Pembrolizumab (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms PREPARE; PREPARE 2.0
- 25 Jan 2024 Status changed from recruiting to completed.
- 01 Sep 2023 This trial has been Discontinued in Germany, according to European Clinical Trials Database record.
- 13 Dec 2016 New trial record